Postconfluent multilayered cell line cultures for selective screening of gemcitabine.
暂无分享,去创建一个
G. Peters | H. Pinedo | H. Pinedo | H M Pinedo | G J Peters | E Smitskamp-Wilms | G Veerman | V W Ruiz van Haperen | V. R. V. Ruiz van Haperen | G. Veerman | E. Smitskamp-Wilms | G. Peters
[1] H. Pinedo,et al. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine. , 1996, Biochemical pharmacology.
[2] Benjamin Rs. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995 .
[3] G. Peters,et al. Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. , 1992, British Journal of Cancer.
[4] S. Kaye. Gemcitabine: current status of phase I and II trials. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Plunkett,et al. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. , 1990, Cancer research.
[6] W. Plunkett,et al. Preclinical characteristics of gemcitabine , 1995, Anti-cancer drugs.
[7] V. Heinemann,et al. 2′,2′-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells , 1989 .
[8] G. Peters,et al. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. , 1991, European journal of cancer.
[9] Kenneth D. Paull,et al. Data Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen , 1992 .
[10] G. Peters,et al. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. , 1994, Cancer research.
[11] T. Lawrence,et al. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. , 1994, Cancer research.
[12] L. Hertel,et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.
[13] G. Peters,et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. , 1995, Seminars in oncology.
[14] J. Neijt,et al. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients , 1995, Anti-cancer drugs.
[15] H. Pinedo,et al. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. , 1993, British Journal of Cancer.
[16] V. Heinemann,et al. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.
[17] V. Heinemann,et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.
[18] G. Peters,et al. Gemcitabine: Future Prospects of Single-Agent and Combination Studies. , 1997, The oncologist.
[19] G. Peters,et al. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. , 1993, Biochemical pharmacology.
[20] L. Hertel,et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.
[21] Laurence H. Baker,et al. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development , 1992, Developments in Oncology.
[22] D. Scudiero,et al. New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.
[23] G. Peters,et al. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. , 1994, Biochemical pharmacology.
[24] G. Peters,et al. Introduction: Gemcitabine - Status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog , 1995 .
[25] Y Z Xu,et al. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. , 1992, Cancer research.
[26] H. Preisler,et al. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy. , 1979, Cancer research.
[27] G. Snow,et al. Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. , 1991, Cancer research.
[28] G. Peters,et al. Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. , 1993, European journal of cancer.
[29] H. Hansen,et al. Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). , 1993, Cancer treatment reviews.
[30] G. Peters,et al. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. , 1994, Biochemical pharmacology.